866-997-4948(US-Canada Toll Free)

Diabetic Foot Ulcers - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Metabolic Disorders

No. of Pages : 136 Pages


This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Diabetic Foot Ulcers and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Diabetic Foot Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Diabetic Foot Ulcers pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Diabetic Foot Ulcers Overview 10
Therapeutics Development 11
Pipeline Products for Diabetic Foot Ulcers Overview 11
Pipeline Products for Diabetic Foot Ulcers Comparative Analysis 12
Diabetic Foot Ulcers Therapeutics under Development by Companies 13
Diabetic Foot Ulcers Therapeutics under Investigation by Universities/Institutes 17
Diabetic Foot Ulcers Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Diabetic Foot Ulcers Products under Development by Companies 22
Diabetic Foot Ulcers Products under Investigation by Universities/Institutes 24
Diabetic Foot Ulcers Companies Involved in Therapeutics Development 25
Derma Sciences, Inc. 25
Cardium Therapeutics, Inc. 26
GlaxoSmithKline plc 27
CardioVascular BioTherapeutics, Inc. 28
Stratatech Corporation 29
Photopharmica Limited 30
Tissue Med Biosciences 31
Reliance Life Sciences Pvt. Ltd. 32
Nanotherapeutics, Inc. 33
Celgene Corporation 34
Kaken Pharmaceutical Co., Ltd. 35
CytoTools AG 36
Indus Biotech Private Limited 37
Phage Pharmaceuticals, Inc. 38
NovaLead Pharma Pvt. Ltd. 39
FirstString Research, Inc. 40
Theravasc, Inc. 41
CoDa Therapeutics, Inc. 42
Adocia 43
EyeGene, Inc. 44
Izun Pharmaceuticals Corporation 45
Praxis Pharmaceuticals Inc. 46
Oneness Biotech Co., Ltd. 47
Aprogen, Inc. 48
Pergamum AB 49
Dipexium Pharmaceuticals LLC 50
Kasiak Research Pvt. Ltd. 51
Diabetic Foot Ulcers Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Target 53
Assessment by Mechanism of Action 56
Assessment by Route of Administration 59
Assessment by Molecule Type 61
Drug Profiles 64
pexiganan acetate - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
DermaPro CI-05 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
trafermin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
WH-1 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
DSC-127 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
CVBT-141B - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
doxycycline - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
GAM-501 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Biochaperone PDGF-BB - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
CODA-001 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
PX-070101 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
ReliDerm-DT - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
PPA-904 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
IZN-6D4 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Granexin - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
CSTC-1 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
esmolol hydrochloride - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
gentamicin sulfate - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
GSK-1278863 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Fibroblast Growth Factor-1 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
PDA-002 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
TMBP-3 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
coagulation factor XIVa (human) - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
rusalatide acetate - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
INDUS-820 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
VLD-02 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
AP-102 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Drug For Wound Healing - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Stromal Cell Therapy For Diabetic Complications - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
EG-Decorin - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Nu-2 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
MT-003 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
CA5-HIF Gene Therapy for Wound and Ulcers - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Cathelicidin - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Drug For Diabetic Foot Ulcer - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
LL-37 - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Refaheal - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Diabetic Foot Ulcers Recent Pipeline Updates 114
Diabetic Foot Ulcers Dormant Projects 125
Diabetic Foot Ulcers Discontinued Products 126
Diabetic Foot Ulcers Product Development Milestones 127
Featured News & Press Releases 127
Jan 16, 2014: Derma Sciences Provides Update on DSC127 Phase 3 Clinical Trials 127
Oct 10, 2013: Pergamum announces final data from Phase I/II study of LL-37 in patients with chronic leg ulcers 127
Sep 10, 2013: Dipexium Provides Locilex Manufacturing Update 128
Jul 09, 2013: Dipexium Pharmaceuticals Announces the Issuance of a New U.S. Patent for Locilex 129
Jun 18, 2013: Daewoong Pharma Enters Into Contract With Abdi Ibrahim To Export Easyef To Turkey 129
Apr 25, 2013: Derma Sciences Begins Screening Patients In Second Phase III Trial With DSC127 For Healing Diabetic Foot Ulcers 130
Mar 18, 2013: Adocia Announces Phase III Development Program For Treatment Of Diabetic Foot Ulcer 131
Feb 06, 2013: Derma Sciences Initiates Enrollment In DSC127 Phase III Trial For Healing Diabetic Foot Ulcers 131
Jan 16, 2013: DermaTools Biotech Launches Phase III Clinical Trial With DermaPro For Treatment Of Diabetic Foot Syndrome 133
Jan 03, 2013: Dipexium Pharma Receives Special Protocol Assessment From FDA For Phase III Trial In Mildly Infected Diabetic Foot Ulcers With Locilex 133

Appendix 135
Methodology 135
Coverage 135
Secondary Research 135
Primary Research 135
Expert Panel Validation 135
Contact Us 136
Disclaimer 136

List of Table


Number of Products under Development for Diabetic Foot Ulcers, H1 2014 11
Number of Products under Development for Diabetic Foot Ulcers Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Development by Companies, H1 2014 (Contd..2) 16
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Development, H1 2014 20
Comparative Analysis by Unknown Stage Development, H1 2014 21
Products under Development by Companies, H1 2014 22
Products under Development by Companies, H1 2014 (Contd..1) 23
Products under Investigation by Universities/Institutes, H1 2014 24
Diabetic Foot Ulcers Pipeline by Derma Sciences, Inc., H1 2014 25
Diabetic Foot Ulcers Pipeline by Cardium Therapeutics, Inc., H1 2014 26
Diabetic Foot Ulcers Pipeline by GlaxoSmithKline plc, H1 2014 27
Diabetic Foot Ulcers Pipeline by CardioVascular BioTherapeutics, Inc., H1 2014 28
Diabetic Foot Ulcers Pipeline by Stratatech Corporation, H1 2014 29
Diabetic Foot Ulcers Pipeline by Photopharmica Limited, H1 2014 30
Diabetic Foot Ulcers Pipeline by Tissue Med Biosciences, H1 2014 31
Diabetic Foot Ulcers Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2014 32
Diabetic Foot Ulcers Pipeline by Nanotherapeutics, Inc., H1 2014 33
Diabetic Foot Ulcers Pipeline by Celgene Corporation, H1 2014 34
Diabetic Foot Ulcers Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2014 35
Diabetic Foot Ulcers Pipeline by CytoTools AG, H1 2014 36
Diabetic Foot Ulcers Pipeline by Indus Biotech Private Limited, H1 2014 37
Diabetic Foot Ulcers Pipeline by Phage Pharmaceuticals, Inc., H1 2014 38
Diabetic Foot Ulcers Pipeline by NovaLead Pharma Pvt. Ltd., H1 2014 39
Diabetic Foot Ulcers Pipeline by FirstString Research, Inc., H1 2014 40
Diabetic Foot Ulcers Pipeline by Theravasc, Inc., H1 2014 41
Diabetic Foot Ulcers Pipeline by CoDa Therapeutics, Inc., H1 2014 42
Diabetic Foot Ulcers Pipeline by Adocia, H1 2014 43
Diabetic Foot Ulcers Pipeline by EyeGene, Inc., H1 2014 44
Diabetic Foot Ulcers Pipeline by Izun Pharmaceuticals Corporation, H1 2014 45
Diabetic Foot Ulcers Pipeline by Praxis Pharmaceuticals Inc., H1 2014 46
Diabetic Foot Ulcers Pipeline by Oneness Biotech Co., Ltd., H1 2014 47
Diabetic Foot Ulcers Pipeline by Aprogen, Inc., H1 2014 48
Diabetic Foot Ulcers Pipeline by Pergamum AB, H1 2014 49
Diabetic Foot Ulcers Pipeline by Dipexium Pharmaceuticals LLC, H1 2014 50
Diabetic Foot Ulcers Pipeline by Kasiak Research Pvt. Ltd., H1 2014 51
Assessment by Monotherapy Products, H1 2014 52
Number of Products by Stage and Target, H1 2014 55
Number of Products by Stage and Mechanism of Action, H1 2014 58
Number of Products by Stage and Route of Administration, H1 2014 60
Number of Products by Stage and Molecule Type, H1 2014 63
Diabetic Foot Ulcers Therapeutics Recent Pipeline Updates, H1 2014 114
Diabetic Foot Ulcers Dormant Projects, H1 2014 125
Diabetic Foot Ulcers Discontinued Products, H1 2014 126

List of Chart


Number of Products under Development for Diabetic Foot Ulcers, H1 2014 11
Number of Products under Development for Diabetic Foot Ulcers Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Products, H1 2014 20
Assessment by Monotherapy Products, H1 2014 52
Number of Products by Top 10 Target, H1 2014 53
Number of Products by Stage and Top 10 Target, H1 2014 54
Number of Products by Top 10 Mechanism of Action, H1 2014 56
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 57
Number of Products by Top 10 Route of Administration, H1 2014 59
Number of Products by Stage and Top 10 Route of Administration, H1 2014 60
Number of Products by Top 10 Molecule Type, H1 2014 61
Number of Products by Stage and Top 10 Molecule Type, H1 2014 62

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *